$MCS

MARCUS CORP

No enriched coverage for $MCS in the last 7 days.

—
$1.4M
GERSHOWITZ DIANE M
0%
See all $MCS insider activity →

AMC vs. MCS: Which Theater Stock Is the Better Buy Today?

AMC and Marcus (MCS) report Q2 2026 earnings growth, with AMC showing 14.2% revenue increase and MCS up 16.6% in theater admissions. AMC's adjusted EBITDA rose 70% to $321.4M, while MCS's theater-adjusted EBITDA increased 37% to $36.3M. MCS has lower leverage (1.1x) and stronger free cash flow, while AMC's recovery hinges on box office growth. Analysts favor MCS for its diversified earnings and higher estimate revisions.

Marcus Corp Q2 Profit Rises; Shares Climb

Marcus Corp. (MCS) reported Q2 results with net earnings up 116.4% to $15.84M, or $0.51/share, and operating income rising to $27.07M from $13.01M. Adjusted EBITDA increased 43% to $46.2M. Total revenue grew 12.5% to $231.74M. Shares were up about 8.7% at $27.14, per NYSE.

MCS sentiment & insider activity

Recent MCS coverage spans financial news, earnings and insider activity.

In the last 30 days, MCS insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.4M). The most active reporter was GERSHOWITZ DIANE M with 1 filing.

What's driving MCS

AlphAI scores every news story that mentions MCS with an AI model for sentiment and relevance, and aggregates insider trades from MARCUS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MCS

Score

AMC vs. MCS: Which Theater Stock Is the Better Buy Today?

AMC and Marcus (MCS) report Q2 2026 earnings growth, with AMC showing 14.2% revenue increase and MCS up 16.6% in theater admissions. AMC's adjusted EBITDA rose 70% to $321.4M, while MCS's theater-adjusted EBITDA increased 37% to $36.3M. MCS has lower leverage (1.1x) and stronger free cash flow, while AMC's recovery hinges on box office growth. Analysts favor MCS for its diversified earnings and higher estimate revisions.

$MCSMed

Marcus Corp Q2 Profit Rises; Shares Climb

Marcus Corp. (MCS) reported Q2 results with net earnings up 116.4% to $15.84M, or $0.51/share, and operating income rising to $27.07M from $13.01M. Adjusted EBITDA increased 43% to $46.2M. Total revenue grew 12.5% to $231.74M. Shares were up about 8.7% at $27.14, per NYSE.

$MCSMed

MARCUS CORP (MCS): Results of Operations and Financial Condition

MARCUS CORP (MCS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MARCUS CORPORATION REPORTS SECOND QUARTER FISCAL 2026 RESULTS Marcus Corporation reports strong net earnings and highest revenue and Adjusted EBITDA in a second quarter since the pandemic; Marcus Theatres and Marcus Hotels & Resorts outperformed their respective indu

$IMAXMed

Nolan’s ’The Odyssey’ eyes $200M global debut, benefiting IMAX and theater stocks By Investing.com

Christopher Nolan’s “The Odyssey” is set to open in theaters Friday with a projected $200M worldwide debut. Variety projects $90M to $100M domestic opening across 3,900 North American theaters. IMAX (IMAX) benefits from limited IMAX 70mm capacity. AMC (AMC) got a July 15 upgrade to Buy with a $3.00 target. Marcus (MCS) and Cinemark (CNK) may also gain. IMAX Q2 2026 earnings are due July 23.

Related tickers